Tags : Akili

Weekly Snapshot

PharmaShots Weekly Snapshot (Jun 15-19, 2020)

 1.  Ultragenyx and Kyowa Kirin’s Crysvita (burosumab) Receive the US FDA’s Approval for the Treatment of Tumor-Induced Osteomalacia  Published: Jun 19, 2020 | Tags: Ultragenyx, Kyowa Kirin, Crysvita, burosumab, Receives, US, FDA, Approval, Treatment, Tumor-Induced Osteomalacia 2.  Pfizer and Sangamo’s Giroctocogene Fitelparvovec (SB-525) Demonstrate Positive Effect in P-I/II Alta Study for Hemophilia A Published: Jun 18, 2020 […]Read More


Akili’s EndeavorRx Receives the US FDA’s Approval as the First

Shots: The FDA’s De novo clearance is based on five clinical studies in 600+ children diagnosed with ADHD, which demonstrated an improved measure of attention. After 4wks., one-third of children had no longer measurable attention deficit on at least one measure of objective attention Change in child’s day-to-day impairments following @1mos. treatment with EndeavorRx which […]Read More

DigiHealth Pharma

Shionogi Signs Development & Commercialization Agreement with Akili for its

Shots: Akili to receive $20M upfront, $105M as development & commercialization milestones, making the total the deal value $125M & royalties on sales of the products. Shionogi to get exclusive development & commercialization rights for Akili’s digital medicine, AKL-T01 and AKL-T02 in Japan and Taiwan Acc. to an agreement, Shionogi will be responsible for regulatory […]Read More